Atossa Genetics Inc
$ 5.83
1.04%
17 Apr - close price
- Market Cap 50,205,000 USD
- Current Price $ 5.83
- High / Low $ 5.94 / 5.66
- Stock P/E N/A
- Book Value 4.57
- EPS -4.04
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.63 %
- 52 Week High 19.35
- 52 Week Low 3.76
About
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$23.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-01 | 2026-03-26 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-31 | 2024-11-11 | 2024-08-12 | 2024-05-13 | 2024-03-28 | 2023-11-13 | 2023-08-14 |
| Reported EPS | 0 | -1.34 | -0.07 | -0.07 | -0.05 | -0.05 | -0.0575 | -0.05 | -0.05 | -0.09 | -0.05 | -0.08 |
| Estimated EPS | -0.0667 | -1.1433 | -0.06 | -0.06 | -0.07 | -0.0633 | -0.06 | -0.06 | -0.07 | -0.06 | -0.07 | -0.06 |
| Surprise | 0.0667 | -0.1967 | -0.01 | -0.01 | 0.02 | 0.0133 | 0.0025 | 0.01 | 0.02 | -0.03 | 0.02 | -0.02 |
| Surprise Percentage | 100% | -17.2046% | -16.6667% | -16.6667% | 28.5714% | 21.0111% | 4.1667% | 16.6667% | 28.5714% | -50% | 28.5714% | -33.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATOS
2026-04-17 20:39:21
Maxim Group analyst Jason McCarthy has maintained a 'Buy' rating for Atossa Therapeutics (ATOS.US) and kept the target price at $20. According to TipRanks data, this analyst has a 32.3% success rate and an average return of -14.7% over the past year. The information provided is for informational purposes only and not an investment recommendation.
2026-04-16 14:09:25
Atossa Therapeutics has settled patent disputes with Intas Pharmaceuticals and Jina Pharmaceuticals regarding Endoxifen-related intellectual property, including challenges before the U.S. Patent and Trademark Office. The agreement preserves Atossa's rights to develop and commercialize Z-endoxifen base, reduces patent portfolio uncertainty, and supports its strategic development plans. Despite a "Neutral" rating from TipRanks' AI Analyst due to weak financial performance, the company anticipates its key U.S. patents on Endoxifen to remain valid.
2026-04-16 13:09:25
Atossa Therapeutics Inc. (NASDAQ: ATOS) has settled a patent dispute regarding Endoxifen intellectual property with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc. The agreement, intended to resolve proceedings before the U.S. Patent and Trademark Office, allows Atossa to continue developing and commercializing Z-endoxifen. This settlement is expected to reduce uncertainty surrounding Atossa's patent portfolio, and its shares saw a nearly 15% jump in the past week.
2026-04-16 12:09:25
Atossa Therapeutics has settled patent disputes with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc., regarding Endoxifen-related intellectual property. This agreement resolves challenges before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board, reducing uncertainty for Atossa's patent portfolio. The settlement also preserves Atossa’s ability to develop and commercialize Z-endoxifen base in its key therapeutic areas of oncology, endocrine dysfunction, and muscular dystrophy.
2026-04-14 13:10:06
Atossa Therapeutics is exploring endoxifen as a potential treatment for Duchenne muscular dystrophy (DMD), as announced by CEO Dr. Steven Quay on the Rare Connection podcast. This initiative represents a significant step in developing new therapies for rare diseases. The company previously revealed breast cancer research and Q4/full year 2025 results, providing context for its current focus on rare diseases.
2026-04-13 20:09:19
Atossa Therapeutics (ATOS) has seen its price target decreased by 31.37% to 44.62. This significant adjustment reflects a revised outlook for the company's valuation.
